The group's principal activities are to acquire, develop, enhance and market branded pharmaceutical products. It operates in three segments: product sales, product development and development services. The product sales segment provides for sales of pharmaceutical product lines of the group and manufactures small quantity products outsourced by other pharmaceutical companies. The product development segment develops drugs and technologies that can be marketed on a license fee or royalty basis. The development service segment provides services to pharmaceutical and biotechnology industries including comprehensive formulation, testing and manufacturing expertise for a fee in addition to providing human clinical trials. On 2-Dec-2003, the group acquired pain products from elan corporation. On 26-Apr-2004, the group sold the m.v.i. And aquasol product lines to mayne pharma inc.